LIST OF CATALYSTS prepared by Sox0407



Q3 Milestones / Upcoming Catalysts

- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting

Past Milestones

- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)

Clinical Trials

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product